OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2020.11266 OL-0-0-11266 Articles Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers ZhaoShou-Feng 1 YinXue-Jing 2 ZhaoWen-Ju 3 LiuLe-Cui 4 WangZhi-Peng 5 Central Laboratories, Qingdao Municipal Hospital, Qingdao, Shandong 266000, P.R. China Department of Pharmacy, Qingdao Mental Health Centre, Qingdao, Shandong 266235, P.R. China Operating Room, Qingdao Jinhua Gynecology Hospital, Qingdao, Shandong 266235, P.R. China Neonatal Department, Wulian County People's Hospital, Wulian, Shandong 262300, P.R. China Marine Science and Engineering College, Qingdao Agricultural University, Qingdao, Shandong 266109, P.R. China Correspondence to: Dr Zhi-Peng Wang, Marine Science and Engineering College, Qingdao Agricultural University, 17 Wenhai Road, Jimo, Qingdao, Shandong 266109, P.R. China, E-mail: wangzp@ysfri.ac.cn 03 2020 08 01 2020 19 3 1673 1682 16022019 16082019 Copyright: © Zhao et al. 2020 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Biglycan (BGN), a key member of the small leucine-rich proteoglycan family, is an important component of the extracellular matrix. Clinical studies have demonstrated that upregulation of BGN is associated with poor prognosis in patients with various types of solid cancer. The present study analyzed the mRNA expression levels of BGN in various types of solid cancer when compared with that in normal tissues via the Oncomine database. The UALCAN, OncoLnc and Kaplan-Meier Plotter databases were additionally used to evaluate the prognostic values of BGN in patients with solid cancer and co-expression gene analysis was conducted using the protein-protein interaction networks of BGN. The present study observed that the mRNA expression levels of BGN were increased in bladder, brain and central nervous system, breast, colorectal, esophageal, gastric, head and neck, lung, ovarian and 28 subtypes of cancer compared with normal tissues. The increased expression of BGN was identified to be associated with a poor outcome in ovarian and gastric cancer. Based on the co-expression network, BGN was identified as the key gene in a 43-gene network. The present findings of increased expression of BGN in solid tumors and its positive association with poor outcome on patient survival indicate that BGN may serve as a prognostic marker and as a target for novel therapeutics for multiple types of cancer.

 biglycan biomarker cancer Introduction

Cancer is considered as one of the four major non-communicable diseases (1). Due to a delay in diagnosis, its poor prognosis and high recurrence rate, cancer is becoming one of the leading causes of mortality worldwide (2,3). Cancer incidence and mortality rates have increased over the last decade. The global cancer burden is estimated to have risen to 18.1 million new cancer cases, and 9.6 million cancer-associated mortalities were reported in 2018 (4), compared with 12.7 million and 7.6 million, respectively, in 2008 (5). Therefore, there is an urgent need to explore novel potential cancer biomarkers that will have beneficial prognostic and therapeutic implications.

Biglycan (BGN; also known as proteoglycan-1 and dermatan sulfate PG-1) is a single-copy gene localized on the long arm of human X chromosome Xq13-qter (6). This gene contains at least two introns and it spans ~6 kb in length (7). BGN is a key member of the small leucine-rich proteoglycan family that resides at the cell surface or in the pericellular space of tissues (8). BGN is typically expressed in the nerve, bone, cartilage, skin and muscles, modulating the morphology, growth, adhesion, bone mineralization, inflammation, migration and differentiation of epithelial cells (9). The upregulation of BGN has been reported in multiple types of solid cancer, including ovarian carcinoma (10), prostate cancer (11), pancreatic cancer (12), gastric cancer (13) and colon cancer (14). Overexpressed BGN has been reported to be associated with the aggressive growth and metastasis of tumors (13,14), and with a worse prognosis for patients with gastric cancer (15) and pancreatic adenocarcinoma (16). These findings suggest that the BGN gene may act as either a potential therapeutic target or prognostic biomarker in multiple types of cancer. However, the transcriptional expression and prognostic value of the BGN gene in human cancers requires further investigation.

The present study investigated the mRNA expression levels of BGN in human normal and cancer tissues, using the Oncomine database. In addition, the prognostic value of BGN mRNA expression in patients with cancer was also assessed using the UALCAN, OncoLnc and the Kaplan-Meier Plotter databases. Finally, co-expression gene analysis was conducted using the protein-protein interaction (PPI) networks of BGN.

 Materials and methods <sec> <title>Analysis of BGN expression in multiple cancers using Oncomine

Oncomine is a cancer microarray database and web-based data-mining platform aimed at facilitating discovery from genome-wide expression analyses, as well as comparing the transcriptome data in multiple types of cancer, respective to normal tissues (17). To date, the Oncomine database contains 19 cancer types, 715 datasets and 86,733 samples, corresponding to ~48 million gene expression measurements. Differential mRNA level analyses of BGN were compared between normal tissues and malignant human tissues in different types of cancer, using the Oncomine database. In the present study, the thresholds were set at 2-fold change, P<1×10−4 and the top 10% gene rank.

 Analysis using the Kaplan-Meier (KM) plotter, UALCAN and OncoLnc databases

The prognostic significance of the mRNA expression levels of BGN in various types of cancer was evaluated using KM plotter (http://www.kmplot.com), UALCAN (http://ualcan.path.uab.edu) and OncoLnc (http://oncolnc.org). These online databases can be used to assess the effect of gene expression on cancer prognosis. The three databases of KM plotter, OncoLnc and UALCAN contain the same RNA-seq data (from TCGA) for 20 http://www.kmplot.com/analysis/index.php?p=service&cancer=pancancer_rnaseq, 21 (18) and 35 (19) types and subtypes of cancer, respectively. KM plotter also contain the gene chip data [from GEO (breast cancer: GSE12276, GSE16391, GSE12093, GSE11121, GSE9195, GSE7390, GSE6532, GSE5327, GSE4922, GSE3494, GSE2990, GSE2034, GSE1456; ovarian cancer: GSE14764, GSE15622, GSE19829, GSE3149, GSE9891, GSE18520, GSE26712; lung cancer: GSE4573, GSE14814, GSE8894, GSE19188, GSE3141, GSE31210, GSE29013, GSE37745; gastric cancer: GSE44740, GSE51725, GSE13911, GSE43346, and GSE3526)] (20–23) for breast cancer (BC), lung cancer (LC), gastric cancer (GC) and ovarian cancer (OC). Therefore, the prognostic significance of the mRNA expression levels of BGN in various types of carcinomas, including BC, LC, GC and OC was evaluated using RNA-seq data and confirmed by gene chip data. The overall survival rate (OS) in patients with other types and subtypes of carcinomas was estimated using RNA-seq by KM plotter, OncoLnc or UALCAN databases.

The KM plotter is able to assess the effect of 54,675 genes on survival using 10,461 cancer samples. In this database, the types and subtypes of cancer samples were observed from RNA-sequencing (RNA-seq) data while the lung (22), ovarian (21), gastric (23), and breast (20) cancer samples were also analyzed from gene chip microarrays.

Patient samples were divided into two cohorts according to the median expression of the BGN gene (high vs. low expression). The present study analyzed the overall survival (OS) in patients using a Kaplan-Meier survival plot. Briefly, the BGN gene was uploaded into the respective databases to obtain the Kaplan-Meier survival plots, in which the number-at-risk was presented below the main plot. Affymetrix ID (or RNA-seq ID), log rank P-value and hazard ratio (HR) with 95% confidence intervals were calculated and displayed on the webpage. P<0.05 was considered to indicate a statistically significant difference.

UALCAN, is an interactive web resource for analyzing cancer transcriptome data, built on PERL-common gateway interface with high quality graphics using JavaScript and Cascading Style Sheets. UALCAN was used to construct an algorithm based on The Cancer Genome Atlas (TCGA) level 3 RNA-seq database (https://portal.gdc.cancer.gov/). UALCAN can provide publication quality graphs and plots depicting gene expressions and patient survival information based on gene expression (19). P<0.05 was considered to indicate a statistically significant difference.

OncoLnc is a tool for interactively exploring survival correlations. OncoLnc contains survival data for 8,647 patients from 21 cancer studies performed by TCGA, along with RNA-seq expression for mRNAs and microRNAs from TCGA and long non-coding RNA expressions from MiTranscriptome (β release) (http://www.mitranscriptome.com/). OncoLnc stores precomputed survival analyses, allowing users to quickly explore survival correlations for up to 21 types of cancer in a single click (18). The BGN gene was uploaded into the database to obtain the patient survival information. P<0.05 was considered to indicate a statistically significant difference.

 Co-expression and PPI network construction

The present study extracted the top 50 co-expressed genes that have similar expression pattern with BGN gene, based on Pearson correlation score across all tumor samples from the GEPIA database (http://gepia.cancerpku.cn/index.html). Then, the 11.0 Search Tool for the Retrieval of Interacting Genes/Proteins database (http://string-db.org/), was used to construct a PPI network with these co-expressed genes (24). The PPI pairs were extracted with a combined score of 0.4. Subsequently, the PPI network was visualized using the Cytoscape 3.7.0 software (http://www.cytoscape.org/).

 Results <sec> <title>Increased expression of BGN in multiple types of solid cancer

As illustrated in Fig. 1, Oncomine contained a total of 421 research studies for the BGN gene. In 78 analyses, BGN exhibited statistically significant differences, 5 of which revealed lower mRNA expression levels in solid tumors compared with normal tissues, while 73 analyses indicated the opposite result (Fig. 1). BGN gene expression was the most upregulated in bladder, brain and central nervous system (CNS), breast, colorectal, gastric, head and neck, pancreatic cancer and other cancer, followed by esophageal, kidney, liver, ovarian cancer, and lung cancer (Fig. 1). Results in the investigation of BGN gene expression have been inconsistent in a number of studies (25–33), including kidney, liver, pancreatic, and prostate cancer. The expression levels of BGN in cervical cancer and melanoma were not significantly changed (Fig. 1). The BGN gene expression status in lymphoma, leukemia, sarcoma and myeloma was not analyzed in this study as they are not classified as solid cancers (34).

Solid cancers, in which BGN was reported to be upregulated consistently in different studies, were examined further in the various cancer subtypes using the Oncomine datasets. The data summarized in Table I revealed that there was a significant increase in expression of BGN in BLC, including subtype of IBLCA) (n=53), when compared with that in normal tissues (n=3) in the study by Blaveri et al (35). The BGN mRNA expression was significantly elevated in brain and CNS cancer, including subtype of GBM (n=130) when compared with normal tissues (n=30) in the study conducted by Bredel et al (36). The mRNA expression of BGN was significantly elevated in BC, including subtypes BRCA, DBC, DCIS, IDBC, IDBCs, IDC, IDC-L, ILBC, ILC, LBC, MBC and TBC (n=2,540) compared with that in normal tissues (n=240), which was performed by Ma et al (37), Curtis et al (38), Karnoub et al (39), Perou et al (40), Zhao et al (41) and TCGA studies (42,43) The mRNA expression of BGN was also significantly upregulated in CC, including subtypes COAD, CMA, RSA, CeAC and READ (n=463), when compared with that in normal tissues (n=150), which was reported in the studies conducted by Kaiser et al (44), Skrzypczak et al (45), Graudens et al (46), TCGA (47), Gaedcke et al (48), and Hong et al (49). BGN mRNA expression was also significantly upregulated in EC, including subtype ESCC (n=84), when compared with that in normal tissues (n=80), which was reported in the studies of Su et al (50), Hu et al (51) and Hao et al (52). BGN mRNA expression was also significantly higher in GC, including subtypes ITGA, DGAC and GMA (n=265), when compared with that in normal tissues (n=171), as reported by Chen et al (53), Cho et al (54), Wang et al (55), D'Errico et al (56) and Cui et al (57). The mRNA expression of BGN was also significantly increased in HNC, including subtype SGACC (n=16) compared with that in normal tissues (n=6) in the study by Frierson et al (58). The mRNA expression of BGN was significantly higher in LC, including subtype SCC (n=34) compared with that in normal tissues (n=28) in the study by Talbot et al (59). The mRNA expression of BGN was increased significantly in OC, including subtypes SSPC and OSC (n=799) compared with that in normal tissues (n=22), as reported by Welsh et al (60), and Bonome et al (61), and studies listed in TCGA (62). The mRNA expression of BGN was increased significantly in other types of cancer, including subtype SBCC (n=15) compared with that in normal tissues (n=4), as reported by Riker et al (63). Therefore, the expression of BGN was significantly increased in human solid cancers, including 10 types and 28 subtypes of carcinoma. These results indicate that the mRNA expression of BGN is elevated in a wide range of tumors, when compared with that in normal tissues.

 High BGN expression and survival outcome in multiple types of solid cancer

The expression of BGN was significantly increased in certain types of human solid cancers, including bladder, brain and CNS, breast, colorectal, gastric, head and neck, esophageal, ovarian, lung and other cancers, however there was no data on the downregulation of the BGN from the database (Table I). The present study used the Kaplan-Meier Plotter, OncoLnc and UALCAN databases to identify the association between survival time and the mRNA levels of BGN in patients with different types and subtypes of solid cancer.

As shown in Table II, BGN gene with a significant association with patient survival can be identified in GC and OC (P<0.05). There is no significant association of BGN upregulation with patient survival in BC, EC (P>0.05), IBC, READ, COAD, and ESCC (P>0.05). The survival rate of patients with LC with P>0.05 in RNA-seq and P<0.05 in microarray analysis requires further investigation. Therefore, high BGN mRNA expression may potentially be associated with the prognosis in patients with BLC, LSCC, and OSC, as the present analyses provided RNA-seq analysis results (P<0.05) without microarray analysis confirmation (Table II). The association between BGN mRNA expression and prognosis in patients with other types of cancer and subtypes of cancer requires further investigation as there is no prognostic data in the KM plotter, OncoLnc and UALCAN database (Table III).

As presented in Fig. 2, high expression of BGN was significantly associated with shorter OS time in patients with GC [HR=1.9 (1.56–2.32), P=1.3×10−10 in microarry analysis; HR=1.59 (1.13–2.24), P=6.8×10−3 in RNA-seq analysis] and OC [HR=1.28 (1.11–1.47), P=4.4×10−4 in microarry analysis; HR=1.45 (1.09–1.93), P=9.3×10−3 in RNA-seq analysis].

In summary, high BGN mRNA expression in gastric cancer and ovarian cancer was significantly associated with poor overall survival. High BGN mRNA expression was indicated to be associated with poor clinical outcome in the prognosis of patients with bladder cancer, lung squamous cell carcinoma, and ovarian serous cystadenocarcinoma. However, the association between BGN mRNA upregulation and prognosis in patients with other types and subtypes of cancer requires further examination.

 PPI network construction

The GEPIA database was used to download the top 50 co-expressed genes, then the PPI was generated (Fig. 3). In the network, BGN directly interacted with 42 neighboring genes, including ANTXR1, AEBP1, CDH11, CTHRC1, EFEMP2, FAP, LEPRE1, LRRC15, LUM, MMP14, MRC2, MXRA5, OLFML2B, PCOLCE, PDGFRB, PXDN, SERPINH1, SFRP2, SPARC, SULF1, TGFβ3, THBS2, THY1, genes of the disintegrin and metalloproteinase gene family, collagen family genes, the integrin subunit gene family and lastly the lysyl oxidase-like gene family, which jointly regulate the occurrence and development of human tumors. Jointly genes with similar expression patterns are likely to have related functions (64). For example, enrichment indicates that BGN-coexpressed genes are at least partially biologically connected in developing multiple cancers (65). The basic interaction between the neighboring genes is the ‘functional association’. The two proteins that both contribute jointly to a specific biological function can interact specifically without touching at all, such as when a transcription factor helps to regulate the expression and production of another protein, or when two enzymes exchange a specific substrate via diffusion. The exact molecular mechanisms in cancer associated with BGN remain unclear (66). BGN upregulation has been implicated in the inflammatory response triggered by transforming growth factor β (TGF-β) (8,67,68). In the PPI network, TGF-β3 may play an important role to regulate the expression of BGN, however, the influence of TGF-β3 needs to be further investigated.

 Discussion

In the present study, the mRNA expression levels of BGN were systematically analyzed, and the results indicated that BGN was upregulated in various types of cancerous tissues, when compared with that in normal tissues. Previous studies have demonstrated that significantly increased levels of BGN are frequently detected in the clinical samples of patients with gastric (13), breast (69), colorectal (70), lung (71), ovarian (10) and pancreatic cancer (16). In addition, high expression of BGN in patients with solid cancer is significantly associated with poor outcome (15). Solid cancer include BLC, brain and CNS cancer, BC, cervical cancer, CC, EC, GC, HNC, kidney cancer, liver cancer, LC, melanoma, OC, pancreatic cancer, prostate cancer (72). Consistent with these studies, the present analyses demonstrated that BGN expression levels were increased in the majority of cancers, such as bladder, brain and central nervous system, breast, colorectal, esophageal, gastric, head and neck, lung, ovarian, and 28 subtype cancers, when compared with that in normal tissues. In addition, the current prognosis analyses revealed that high tissue BGN expression predicts worse survival in GC and OC. High BGN mRNA expression was associated with poor overall survival in patients with BLC, LSCC, and OSC. Therefore, BGN may be employed as either a novel prognostic biomarker or as a promising therapeutic target for human carcinomas, which is consistent with the findings of previous reports (15,73). The 43 genes with similar expression patterns are likely to have related functions in the aggressive growth and metastasis of cancers (64). In the PPI network, the genes of AEBP1, MMP14, OLFML2B, PDGFRB, SERPINE1, SPARC, SFRP2, COL1A2, COL6A3, THBS2, COL5A2, COL11A1, FAP, MXRA5 and THY1 were upregulated in solid cancer tissues, and significantly associated with the overall survival of patients with cancer (74–82). Some genes in the PPI network, including AEBP1, OLFML2B, PDGFRB, SERPINE1, COL1A2, COL6A3, and THBS2 have been reported to be associated with metastasis, invasion and migration in cancer cells (74,76,80,83,84). The enrichment of BGN-coexpressed genes indicates that the proteins are at least partially biologically connected as a group (64). However, a detailed understanding of the mechanism associated with the function of BGN is currently lacking; therefore, further functional studies are warranted in the future. In addition, the BGN protein expression levels or the signaling pathways potentially involved require further investigation. Finally, studies utilizing larger cohorts, specific cancers, or larger prospective studies also need to be conducted in order to validate the prognostic values of BGN.

In summary, the present study comprehensively analyzed the mRNA expression levels and prognostic value of BGN in the most common types of cancer, and the results indicated that BGN exhibited significantly high expression levels in cancer tissues compared with normal tissues in multiple types of cancer. The present findings indicated that BGN may serve as a promising prognostic biomarker and therapeutic target for patients with BLCA and STAD.

 Acknowledgements

Not applicable.

 Funding

No funding was received.

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

SFZ conceived and designed the study. XJY, WJZ, LCL and ZPW made substantial contributions to the design of the current study, acquisition of data, interpretation of data and revising the manuscript. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References ChakerLFallaAvan der LeeSJMukaTImoDJaspersLColpaniVMendisSChowdhuryRBramerWMThe global impact of non-communicable diseases on macro-economic productivity: A systematic reviewEur J Epidemiol30357395201510.1007/s10654-015-0026-525837965 PatelSADeMicheleAAdding adjuvant systemic treatment after neoadjuvant therapy in breast cancer: Review of the dataCurr Oncol Rep1956201710.1007/s11912-017-0613-628733827 MillerKDNogueiraLMariottoABRowlandJHYabroffKRAlfanoCMJemalAKramerJLSiegelRLCancer treatment and survivorship statistics, 2019CA Cancer J Clin69363385201910.3322/caac.2156531184787 SiegelRLMillerKDJemalACancer statistics, 2019CA Cancer J Clin69734201910.3322/caac.2155130620402 FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008Int J Cancer12728932917201010.1002/ijc.2551621351269 GeerkensCVetterUJustWFedarkoNSFisherLWYoungMFTermineJDRobeyPGWöhrleDVogelWThe X-chromosomal human biglycan gene BGN is subject to X inactivation but is transcribed like an X-Y homologous geneHum Genet964452199510.1007/BF002141857607653 McBrideOWFisherLWYoungMFLocalization of PGI (biglycan, BGN) and PGII (decorin, DCN, PG-40) genes on human chromosomes Xq13-qter and 12q, respectivelyGenomics6219225199010.1016/0888-7543(90)90560-H1968422 NastaseMVYoungMFSchaeferLBiglycan: A multivalent proteoglycan providing structure and signalsJ Histochem Cytochem60963975201210.1369/002215541245638022821552 FallonJRMcNallyEMNon-Glycanated biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne muscular dystrophy therapeuticsMatrix Biol68-69616627201810.1016/j.matbio.2018.02.01629481844 KocbekVHevir-KeneNBersingerNAMuellerMDRižnerTLIncreased levels of biglycan in endometriomas and peritoneal fluid samples from ovarian endometriosis patientsGynecol Endocrinol30520524201410.3109/09513590.2014.89805524641675 JacobsenFKraftJSchroederCHube-MaggCKluthMLangDSSimonRSauterGIzbickiJRClauditzTSUp-regulation of biglycan is associated with poor prognosis and PTEN deletion in patients with prostate cancerNeoplasia19707715201710.1016/j.neo.2017.06.00328830008 WeberCKSommerGMichlPFenstererHWeimerMGansaugeFLederGAdlerGGressTMBiglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell linesGastroenterology121657667200110.1053/gast.2001.2722211522750 HuLDuanYTLiJFSuLPYanMZhuZGLiuBYYangQMBiglycan enhances gastric cancer invasion by activating FAK signaling pathwayOncotarget518851896201410.18632/oncotarget.187124681892 XingXGuXMaTYeHBiglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancerTumour Biol3617731780201510.1007/s13277-014-2779-y25371074 WangBLiGXZhangSGWangQWenYGTangHMZhouCZXingAYFanJWYanDWBiglycan expression correlates with aggressiveness and poor prognosis of gastric cancerExp Biol Med (Maywood)23612471253201110.1258/ebm.2011.01112421998129 AprileGAvelliniCReniMMazzerMFoltranLRossiDCeredaSIaizaEFasolaGPigaABiglycan expression and clinical outcome in patients with pancreatic adenocarcinomaTumor Biol34131137201310.1007/s13277-012-0520-2 RhodesDRYuJShankerKDeshpandeNVaramballyRGhoshDBarretteTPandeyAChinnaiyanAMONCOMINE: A cancer microarray database and integrated data-mining platformNeoplasia616200410.1016/S1476-5586(04)80047-215068665 AnayaJOncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and lncRNAsPeerJ Computer Sci2e67201610.7717/peerj-cs.67 ChandrashekarDSBashelBBalasubramanyaSAHCreightonCJPonce-RodriguezIChakravarthiBVSKVaramballySUALCAN: A portal for facilitating tumor subgroup gene expression and survival analysesNeoplasia19649658201710.1016/j.neo.2017.05.00228732212 GyörffyBLanczkyAEklundACDenkertCBudcziesJLiQSzallasiZAn online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patientsBreast Cancer Res Treat123725731201010.1007/s10549-009-0674-920020197 GyőrffyBLánczkyASzállásiZImplementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patientsEndocr Relat Cancer19197208201210.1530/ERC-11-032922277193 GyőrffyBSurowiakPBudcziesJLánczkyAOnline survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancerPLoS One8e82241201310.1371/journal.pone.008224124367507 SzászAMLánczkyANagyÁFörsterSHarkKGreenJEBoussioutasABusuttilRSzabóAGyőrffyBCross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patientsOncotarget74932249333201610.18632/oncotarget.1033727384994 SzklarczykDFranceschiniAWyderSForslundKHellerDHuerta-CepasJSimonovicMRothASantosATsafouKPSTRING v10: Protein-protein interaction networks, integrated over the tree of lifeNucleic Acids Res43D447D452201510.1093/nar/gku100325352553 ChenXCheungSTSoSFanSTBarryCHigginsJLaiKMJiJDudoitSNgIOGene expression patterns in human liver cancersMol Biol Cell1319291939200210.1091/mbc.02-02-002312058060 HigginsJPShinghalRGillHReeseJHTerrisMCohenRJFeroMPollackJRvan de RijnMBrooksJDGene expression patterns in renal cell carcinoma assessed by complementary DNA microarrayAm J Pathol162925932200310.1016/S0002-9440(10)63887-412598325 Iacobuzio-DonahueCAMaitraAOlsenMLoweAWvan HeekNTRostyCWalterKSatoNParkerAAshfaqRExploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarraysAm J Pathol16211511162200310.1016/S0002-9440(10)63911-912651607 BuchholzMBraunMHeidenblutAKestlerHAKlöppelGSchmiegelWHahnSALüttgesJGressTMTranscriptome analysis of microdissected pancreatic intraepithelial neoplastic lesionsOncogene2466266636200510.1038/sj.onc.120880416103885 SegaraDBiankinAVKenchJGLanguschCCDawsonACSkalickyDAGotleyDCColemanMJSutherlandRLHenshallSMExpression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasiaClin Cancer Res1135873596200510.1158/1078-0432.CCR-04-181315867264 BadeaLHerleaVDimaSODumitrascuTPopescuICombined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epitheliaHepatogastroenterology5520162027200819260470 MasVRMalufDGArcherKJYanekKKongXKulikLFreiseCEOlthoffKMGhobrialRMMcIverPFisherRGenes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinomaMol Med158594200910.2119/molmed.2008.0011019098997 YusenkoMVKuiperRPBoetheTLjungbergBvan KesselAGKovacsGHigh-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomasBMC Cancer9152200910.1186/1471-2407-9-15219445733 RoesslerSJiaHLBudhuAForguesMYeQHLeeJSThorgeirssonSSSunZTangZYQinLXWangXWA unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patientsCancer Res701020210212201010.1158/0008-5472.CAN-10-260721159642 FranzmannECarcinomaEncyclopedia of Behavioral MedicineGellmanMDTurnerJRSpringer New YorkNew York, NY329330201310.1007/978-1-4419-1005-9_162 BlaveriESimkoJPKorkolaJEBrewerJLBaehnerFMehtaKDevriesSKoppieTPejavarSCarrollPWaldmanFMBladder cancer outcome and subtype classification by gene expressionClin Cancer Res1140444055200510.1158/1078-0432.CCR-04-240915930339 BredelMBredelCJuricDHarshGRVogelHRechtLDSikicBIFunctional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomasCancer Res6586798689200510.1158/0008-5472.CAN-05-120416204036 MaXJDahiyaSRichardsonEErlanderMSgroiDCGene expression profiling of the tumor microenvironment during breast cancer progressionBreast Cancer Res11R7200910.1186/bcr222219187537 CurtisCShahSPChinSFTurashviliGRuedaOMDunningMJSpeedDLynchAGSamarajiwaSYuanYThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature486346352201210.1038/nature1098322522925 KarnoubAEDashABVoAPSullivanABrooksMWBellGWRichardsonALPolyakKTuboRWeinbergRAMesenchymal stem cells within tumour stroma promote breast cancer metastasisNature449557563200710.1038/nature0618817914389 PerouCMSørlieTEisenMBvan de RijnMJeffreySSReesCAPollackJRRossDTJohnsenHAkslenLAMolecular portraits of human breast tumoursNature406747752200010.1038/3502109310963602 ZhaoHLangerodAJiYNowelsKWNeslandJMTibshiraniRBukholmIKKåresenRBotsteinDBørresen-DaleALJeffreySSDifferent gene expression patterns in invasive lobular and ductal carcinomas of the breastMol Biol Cell1525232536200410.1091/mbc.e03-11-078615034139 Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumoursNature4906170201210.1038/nature1141223000897 CirielloGGatzaMLBeckAHWilkersonMDRhieSKPastoreAZhangHMcLellanMYauCKandothCComprehensive molecular portraits of invasive lobular breast cancerCell163506519201510.1016/j.cell.2015.09.03326451490 KaiserSParkYKFranklinJLHalbergRBYuMJessenWJFreudenbergJChenXHaigisKJeggaAGTranscriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancerGenome Biol8R131200710.1186/gb-2007-8-7-r13117615082 SkrzypczakMGorycaKRubelTPaziewskaAMikulaMJaroszDPachlewskiJOledzkiJOstrowskiJModeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliabilityPLoS One5piie13091201010.1371/journal.pone.001309120957034 GraudensEBoulangerVMollardCMariage-SamsonRBarletXGrémyGCouillaultCLajémiMPiatier-TonneauDZaborskiPDeciphering cellular states of innate tumor drug responsesGenome Biol7R19200610.1186/gb-2006-7-3-r1916542501 Cancer Genome Atlas NetworkMuznyDMBainbridgeMNChangKDinhHHDrummondJAFowlerGKovarCLLewisLRMorganMBComprehensive molecular characterization of human colon and rectal cancerNature487330337201210.1038/nature1125222810696 GaedckeJGradeMJungKCampsJJoPEmonsGGehoffASaxUSchirmerMBeckerHMutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomasGenes Chromosomes Cancer4910241034201010.1002/gcc.2081120725992 HongYDowneyTEuKWKohPKCheahPYA ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeuticsClin Exp Metastasis278390201010.1007/s10585-010-9305-420143136 SuHHuNYangHHWangCTakikitaMWangQHGiffenCCliffordRHewittSMShouJZGlobal gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypesClin Cancer Res1729552966201110.1158/1078-0432.CCR-10-272421385931 HuNCliffordRJYangHHWangCGoldsteinAMDingTTaylorPRLeeMPGenome wide analysis of DNA copy number neutral loss of heterozygosity (CNNLOH) and its relation to gene expression in esophageal squamous cell carcinomaBMC Genomics11576201010.1186/1471-2164-11-57620955586 HaoYTriadafilopoulosGSahbaiePYoungHSOmaryMBLoweAWGene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinomaGastroenterology131925933200610.1053/j.gastro.2006.04.02616952561 ChenXLeungSYYuenSTChuKMJiJLiRChanASLawSTroyanskayaOGWongJVariation in gene expression patterns in human gastric cancersMol Biol Cell1432083215200310.1091/mbc.e02-12-083312925757 ChoJYLimJYCheongJHParkYYYoonSLKimSMKimSBKimHHongSWParkYNGene expression signature-based prognostic risk score in gastric cancerClin Cancer Res1718501857201110.1158/1078-0432.CCR-10-218021447720 WangQWenYGLiDPXiaJZhouCZYanDWTangHMPengZHUpregulated INHBA expression is associated with poor survival in gastric cancerMed Oncol297783201210.1007/s12032-010-9766-y21132402 D'ErricoMde RinaldisEBlasiMFVitiVFalchettiMCalcagnileASeraFSaievaCOttiniLPalliDGenome-wide expression profile of sporadic gastric cancers with microsatellite instabilityEur J Cancer45461469200910.1016/j.ejca.2008.10.032 CuiJChenYChouWCSunLChenLSuoJNiZZhangMKongXHoffmanLLAn integrated transcriptomic and computational analysis for biomarker identification in gastric cancerNucleic Acids Res3911971207201110.1093/nar/gkq96020965966 FriersonHFJrEl-NaggarAKWelshJBSapinosoLMSuAIChengJSakuTMoskalukCAHamptonGMLarge scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinomaAm J Pathol16113151323200210.1016/S0002-9440(10)64408-212368205 TalbotSGEstiloCMaghamiESarkariaISPhamDKO-CharoenratPSocciNDNgaiICarlsonDGhosseinRGene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lungCancer Res6530633071200510.1158/0008-5472.CAN-04-198515833835 WelshJBZarrinkarPPSapinosoLMKernSGBehlingCAMonkBJLockhartDJBurgerRAHamptonGMAnalysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancerProc Natl Acad Sci USA9811761181200110.1073/pnas.98.3.117611158614 BonomeTLevineDAShihJRandonovichMPise-MasisonCABogomolniyFOzbunLBradyJBarrettJCBoydJBirrerMJA gene signature predicting for survival in suboptimally debulked patients with ovarian cancerCancer Res6854785486200810.1158/0008-5472.CAN-07-659518593951 Cancer Genome Atlas Research NetworkIntegrated genomic analyses of ovarian carcinomaNature474609615201110.1038/nature1016621720365 RikerAIEnkemannSAFodstadOLiuSRenSMorrisCXiYHowellPMetgeBSamantRSThe gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasisBMC Med Genomics113200810.1186/1755-8794-1-1318442402 TangZLiCKangBGaoGLiCZhangZGEPIA: A web server for cancer and normal gene expression profiling and interactive analysesNucleic Acids Res45W98W102201710.1093/nar/gkx24728407145 SzklarczykDGableALLyonDJungeAWyderSHuerta-CepasJSimonovicMDonchevaNTMorrisJHBorkPSTRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasetsNucleic Acids Res47D607D613201910.1093/nar/gky113130476243 AppunniSAnandVKhandelwalMGuptaNRubensMSharmaASmall leucine rich proteoglycans (decorin, biglycan and lumican) in cancerClin Chim Acta49117201910.1016/j.cca.2019.01.00330629950 SchaeferLBabelovaAKissEHausserHJBaliovaMKrzyzankovaMMarscheGYoungMFMihalikDGötteMThe matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophagesJ Clin Invest11522232233200510.1172/JCI2375516025156 HildebrandARomarisMRasmussenLMHeinegårdDTwardzikDRBorderWARuoslahtiEInteraction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor betaBiochem J302527534199410.1042/bj30205278093006 BischofAGYükselDMammotoTMammotoAKrauseSIngberDEBreast cancer normalization induced by embryonic mesenchyme is mediated by extracellular matrix biglycanIntegr Biol (Camb)510451056201310.1039/c3ib40103k23817524 LiuBXuTXuXCuiYXingXBiglycan promotes the chemotherapy resistance of colon cancer by activating NF-kappaB signal transductionMol Cell Biochem449285294201810.1007/s11010-018-3365-129761248 YangZWenYQianLHospitalZUp-regulation of biglycan is associated with malignant phenotype of nonsmall cell lung cancerJ Med Res4541462016 FerlayJColombetMSoerjomataramIMathersCParkinDMPiñerosMZnaorABrayFEstimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInt J Cancer14419411953201910.1002/ijc.3193730350310 AppunniSAnandVKhandelwalMSethAMathurSSharmaAAltered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): Plausible diagnostic marker in urothelial carcinoma of bladderTumour Biol391010428317699112201710.1177/101042831769911228459201 LiuJYJiangLLiuJJHeTCuiYHQianFYuPWAEBP1 promotes epithelial-mesenchymal transition of gastric cancer cells by activating the NF-κB pathway and predicts poor outcome of the patientsSci Rep811955201810.1038/s41598-018-29878-630097586 KasurinenAGramolelliSHagströmJLaitinenAKokkolaAMikiYLehtiKYashiroMOjalaPMBöckelmanCHaglundCHigh tissue MMP14 expression predicts worse survival in gastric cancer, particularly with a low PROX1Cancer Med869957005201910.1002/cam4.257631560170 LiuJLiuZZhangXGongTYaoDBioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing toolsBMC Cancer19227201910.1186/s12885-019-5937-130866865 WangGShiBFuYZhaoSQuKGuoQLiKSheJHypomethylated gene NRP1 is co-expressed with PDGFRB and associated with poor overall survival in gastric cancer patientsBiomed Pharmacother11113341341201910.1016/j.biopha.2019.01.02330841447 LiaoPLiWLiuRTeerJKXuBZhangWLiXMcleodHLHeYGenome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancerOnco Targets Ther1169696980201810.2147/OTT.S17393430410354 WangHDuanXLQiXLMengLXuYSWuTDaiPGConcurrent Hypermethylation of SFRP2 and DKK2 Activates the Wnt/β-catenin pathway and is associated with poor prognosis in patients with gastric cancerMol Cells404553201710.14348/molcells.2017.224528152305 AoRGuanLWangYWangJNSilencing of COL1A2, COL6A3, and THBS2 inhibits gastric cancer cell proliferation, migration, and invasion while promoting apoptosis through the PI3k-Akt signaling pathwayJ Cell Biochem11944204434201810.1002/jcb.2652429143985 ZhuoCLiXZhuangHTianSCuiHJiangRLiuCTaoRLinXElevated THBS2, COL1A2, and SPP1 expression levels as predictors of gastric cancer prognosisCell Physiol Biochem4013161324201610.1159/00045318427997896 HaoSLvJYangQWangALiZGuoYZhangGIdentification of key genes and circular RNAs in human gastric cancerMed Sci Monit2524882504201910.12659/MSM.91538230948703 SuzukiSDobashiYHatakeyamaYTajiriRFujimuraTHeldinCHOoiAClinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancerBMC Cancer10659201010.1186/1471-2407-10-65921118571 MazzoccoliGPazienzaVPanzaAValvanoMRBenegiamoGVinciguerraMAndriulliAPiepoliAARNTL2 and SERPINE1: Potential biomarkers for tumor aggressiveness in colorectal cancerJ Cancer Res Clin Oncol138501511201210.1007/s00432-011-1126-622198637

mRNA expression levels of BGN in different types of cancer from the Oncomine database. The schematic reveals the numbers of datasets with statistically significant mRNA overexpression (red) or underexpression (blue) of the target gene. Darker red indicates higher BGN expression, Darker blue indicates lower BGN expression. The color is determined by the best gene rank percentile for the analyses within the cell. The number in each cell represents the number of analyses that met the thresholds of: Gene, BGN; analysis type, cancer vs. normal; and data type, mRNA. The thresholds were set at 2-fold change, P<1×10−4 and the top 10% gene rank. For cervical cancer, melanoma, myeloma and prostate cancer, there was no analysis (white cell) that met the aforementioned thresholds. The gene rank was analyzed using the percentile of target gene in the top of all genes measured in each analysis. BGN, biglycan; CNS, central nervous system.

OS curves of patients with different types of cancer divided by BGN expression. High expression levels of the BGN gene exhibited a significant association with lower OS time in patients with (A) gastric cancer (gene chip data), (B) gastric cancer (RNA-seq data), (C) ovarian cancer (gene chip data), (D) ovarian cancer (RNA-seq data). The plots were generated using the KM plotter database. The red lines indicate patients with BGN gene expression above the median value, and the black lines indicate patients with BGN gene expression below the median value. OS, overall survival; BGN, biglycan; HR, hazard ratio.

PPI network for BGN and its potential interacting proteins. Genes that were co-expressed in cancer together with BGN were extracted from the GEPIA database, and then a PPI network was established using the STRING database and visualized using the Cytoscape software. TGFβ3 was highlighted in yellow because it may play an important role to regulate the expression of BGN. PPI, protein-protein interactions; BGN, biglycan; TGFβ3, transforming growth factor β3.

Significant changes of biglycan mRNA expression between different subtypes of bladder, brain and CNS, breast, colorectal, esophageal, gastric, head and neck, lung, ovarian, other types of cancer and 28 subtypes cancer.

Type of cancer Cancer Subtype (n) Normal, n Fold change t-test P-value Rank, % (Refs.)
Bladder Infiltrating Bladder Urothelial Carcinoma (IBLCA) (53) 3 2.391 6.799 7.02×10−7 1 (35)
Brain and CNS Glioblastoma (GBM) (27) 4 3.055 13.066 6.77×10−14 1 (36)
Glioblastoma (GBM) (22) 3 13.32 7.773 4.92×10−5 4
Glioblastoma (GBM) (81) 23 2.163 7.599 7.14×10−11 7
Breast Ductal Breast Carcinoma in Situ Stroma (DCIS) (11) 14 13.191 7.155 2.28×10−11 (37)
Invasive Ductal Breast Carcinoma Stroma (IDC) (9) 14 7.232 5.357 1.27×10−6 1
Invasive Lobular Breast Carcinoma (ILC) (36) 61 3.312 13.142 1.58×10−22   1 (42,43)
Invasive Breast Carcinoma (BRCA) (76) 61 3.131 14.001 1.22×10−27 1
Male Breast Carcinoma (MBC) (3) 61 4.661 10.406 3.76×10−5 4
Mixed Lobular and Ductal Breast Carcinoma (IDC-L) (7) 61 2.780 5.576 8.56×10−5 4
Invasive Ductal Breast Carcinoma (IDC) (389) 61 2.714 14.829 5.11×10−25 5
Tubular Breast Carcinoma (TBC) (67) 144 3.014 18.174 4.05×10−41 1 (38)
Invasive Lobular Breast Carcinoma (ILBC) (148) 144 3.087 19.715 8.92×10−56 1
Invasive Ductal and Invasive Lobular Breast 144 2.885 14.973 4.81×10−33 1
Carcinoma (IDC and ILC) (90)
Breast Carcinoma (BC) (14) 144 2.884 5.505 3.00×10−5 4
Invasive Ductal Breast Carcinoma (IDC) (1556) 144 2.988 26.199 1.50×10−62 5
Medullary Breast Carcinoma (MBC) (32) 144 2.256 6.302 1.13×10−7 9
Invasive Ductal Breast Carcinoma Stroma (IDBCs) (7) 15 3.546 6.337 2.70×10−6 1 (39)
Ductal Breast Carcinoma (DBC) (36) 3 3.337 9.550 7.02×10−6 2 (40)
Lobular Breast Carcinoma (LBC) (21) 3 3.337 10.925 1.22×10−7 1 (41)
Invasive Ductal Breast Carcinoma (IDBC) (38) 3 6.756 12.230 1.80×10−6 5
Colorectal Colon Adenocarcinoma (COAD) (41) 5 3.200 13.125 1.74×10−15 1 (44)
Colon Mucinous Adenocarcinoma (CMA) (13) 5 2.942 9.781 6.65 ×10−8 1
Rectosigmoid Adenocarcinoma (RSA) (10) 5 3.799 7.377 4.85×10−6 2
Cecum Adenocarcinoma (CeAC) (17) 5 3.039 6.529 1.17×10−6 4
Colorectal Carcinoma (CC) (36) 24 4.795 8.671 3.32×10−12 1 (45)
Colorectal Carcinoma (CC) (18) 12 2.563 5.442 5.94×10−6 4 (46)
Colon Carcinoma (cc) (5) 10 7.740 15.965 3.60×10−10 2 (45)
Colon Adenocarcinoma (COAD) (5) 10 4.099 14.219 6.23×10−9 2
Colon Mucinous Adenocarcinoma (CMA) (101) 22 2.324 11.956 3.48×10−19 3 (47)
Rectal Adenocarcinoma (READ) (22) 22 3.772 10.097 4.62×10−11 3
Rectal Adenocarcinoma (READ) (60) 22 2.065 8.557 3.90×10−13 7
Rectal Adenocarcinoma (READ) (65) 65 2.068 11.751 2.16×10−19 6 (48)
Colorectal Carcinoma (CC) (70) 12 3.508 9.208 4.02×10−9 7 (49)
Esophageal Esophageal Squamous Cell Carcinoma (ESCC) (53) 53 2.795 10.666 3.73×10−17 2 (50)
Esophageal Squamous Cell Carcinoma (ESCC) (17) 17 2.964 5.524 3.47×10−6 5 (51)
Esophageal Adenocarcinoma (EA) (14) 10 10.158 8.460 8.51×10−5 5 (52)
Gastric Gastric Intestinal Type Adenocarcinoma(ITGA) (62) 29 4.852 18.317 4.31×10−32 1 (53)
Diffuse Gastric Adenocarcinoma (DGAC) (13) 29 6.483 23.103 1.13×10−17 1
Gastric mixed Adenocarcinoma (GMA) (8) 29 9.700 11.684 1.63×10−6 1
Diffuse Gastric Adenocarcinoma (DGAC) (31) 19 3.287 8.446 2.38×10−11 1 (54)
Gastric Intestinal Type Adenocarcinoma (ITGA) (20) 19 3.038 6.251 4.01×10−7 1
Gastric Cancer (GC) (15) 12 5.721 5.853 2.49×10−6 1 (55)
Diffuse Gastric Adenocarcinoma (DGAC) (6) 31 6.207 5.794 9.36×10−5 2 (56)
Gastric Mixed Adenocarcinoma (GMA) (4) 31 9.737 8.460 1.49×10−5 3
Gastric Intestinal Type Adenocarcinoma (ITGA) (26) 31 4.413 7.512 2.59×10−9 5
Gastric Cancer (GC) (80) 80 3.226 5.032 6.55×10−7 2 (57)
Head and neck Salivary Gland Adenoid Cystic Carcinoma (SGACC) (16) 6 4.703 11.107 5.90×10−10 1 (58)
Lung Squamous Cell Carcinoma (SCC) (34) 28 2.177 5.194 1.45×10−6 10 (59)
Ovarian Ovarian Serous Surface Papillary Carcinoma (SSPC) (28) 4 36.947 7.443 2.62×10−8 2 (60)
Ovarian Carcinoma (OC) (185) 10 3.105 10.018 9.77×10−9 7 (61)
Ovarian Serous Cystadenocarcinoma (OSC) (586) 8 2.706 8.141 2.09×10−5 10 (62)
Other cancer Skin Basal Cell Carcinoma (SBCC) (15) 4 5.312 11.144 1.81 ×10−9 1 (63)

Cancer samples were compared with normal tissues. CNS, central nervous system; TCGA, The Cancer Genome Atlas; IBLCA Infiltrating Bladder Urothelial Carcinoma.

Overall survival of patients with different types of cancer with overexpressed BGN gene.

Cancer types RNA-seq P-value (database) gene chip P-value (database)
Breast cancer 0.2556a 0.7210a
Esophageal adenocarcinoma 0.0965a N/A
Lung cancer 0.3010a 0.0002a
Gastric cancer 0.0068a 1.3×10−10a
Ovarian cancer 0.0093a 0.0004a
Bladder cancer 0.0025a N/A

Calculated using

Kaplan-Meier Plotter databases with RNA-seq data and gene chip data. BGN, biglycan; N/A, not applicable.

Overall survival of patients with different subtypes of cancer with overexpressed BGN gene.

Cancer subtype RNA-seq P-value (database) gene chip P-value (database)
Lung squamous cell carcinoma 0.0111a N/A
Ovarian serous cystadenocarcinoma 0.0290c N/A
Breast invasive carcinoma 0.9400c N/A
Colon adenocarcinoma 0.0963b N/A
Rectum adenocarcinoma 0.1776a N/A
Esophageal Squamous 0.2707a N/A
Cell Carcinoma

Calculated using

Kaplan-Meier Plotter databases

OncoLnc

UALCAN with RNA-seq data. BGN, biglycan; N/A, not applicable.